SureTrader Nadex Advertisement Interactive Brokers Advertisement SureTrader
Home > Boards > US OTC > Biotechs >

U.S. Stem Cell Inc. (USRM)

Add USRM Price Alert      Hide Sticky   Hide Intro
Moderator: TheHungryHippo, Papa Bear, BluSkies, StaleyCornell, buythebuy, mtlebomac
Search This Board: 
Last Post: 5/23/2017 8:07:10 PM - Followers: 862 - Board type: Free - Posts Today: 486



Bioheart, Inc. is committed to the discovery and development of autologous cellular therapies to treat a variety of degenerative diseases, as well as the continuation of our ongoing research for the treatment of heart failure, cardiovascular and perioheral vascular disease. 


The US. Stem Cell Inc. Vision
Our vision is to improve the quality of patients’ lives, while reducing hospitalizations and healthcare costs. 
Bioheart is and will continue to be recognized by physicians and patients as the world’s leader in providing 
innovative treatment and management of patients with severe cardiovascular and peripheral vascular 
disease.We are also focused on the discovery, development and commercialization of autologous cell therapies 
for the treatment of degenerative diseases.




Mike Tomás

President & CEO

Mike Tomas. Mr. Mike Tomas was appointed President and Chief Executive Officer and a member of our Board of Directors on June 19, 2010. Mike Tomas was appointed as the Company’s President and Chief Executive Officer, and as a director on June 19, 2010. Mr. Tomas has been President for the past nine years of The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart since 2001. In 2003, he joined Bioheart’s Board of Directors as the independent representative of The ASTRI Group. ASTRI provides capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise $40M in venture capital to form Ineto, an integrated customer communications software solution that was successfully sold in 2001.
Mr. Tomas sits on the boards of Avisena (revenue cycle management company for medical practices), SilverSky (fka Perimeter Internetworking) (SaaS/managed security services provider for medical practices and financial institutions), Rokk3r Labs (a digital and mobile products developer and portfolio), Bioheart (adult stem cell development for heart muscle tissue repair) and is the current chairman of Florida International University’s Global Entrepreneurship Center. He is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner — and winner of top communications, medical innovations, education and entrepreneurial awards. Mr. Tomas holds a Masters of Business Administration from the University of Miami and a Bachelor’s degree from Florida International University.

Kristin Comella

Chief Scientific Officer

Kristin Comella. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has many years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.  On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors.

Dr. William P. Murphy, Jr.

William P. Murphy, Jr., M.D. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents. He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame


Executive Officers and Directors

Set forth below is information regarding our executive officers and directors as of December 31, 2013

Mike Tomas 48 Director, President and Chief Executive Officer, Chief Financial Officer
William P. Murphy, Jr., M.D. 90 Director, Chairman of the Board
Mark P. Borman  59  Director
Charles A. Hart  53 Director
Sam Ahn  59 Director
Kristen Comella  37 Director, Chief Scientific Officer
Sheldon T. Anderson 63 Director


Business Strategy

 Our principal objective is to become a leading regenerative medicine company that discovers, develops and commercializes novel, autologous cell therapies, and related devices, for the treatment and improved care of patients suffering from chronic and acute heart damage as well as lower limb ischemia. Our secondary objective is the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases.  The number of heart failure patients is expected to increase from 25 million worldwide today to over 50 million in five years. Our focus is on serving these patients. To achieve our primary objective, we plan to pursue the following strategies:

  • - Obtain initial regulatory approval of MyoCell and/or MyoCell SDF-1 by targeting patients with severe heart damage. 
    - Continue existing studies with adipose derived stem cells and endothelial progenitor cells.
    - Continue to develop our pipeline of cell-based therapies and related devices for the treatment of chronic and acute heart damage. 
    - Develop our sales and marketing capabilities. 
    - Continue to refine our MyoCell and MyoCell SDF-1 cell culturing processes.
    - Expand and enhance our intellectual property rights.
    - License, acquire and/or develop complementary products and technologies. 

USRM - Daily Candlesticks


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
USRM News: Quarterly Report (10-q) 05/02/2017 04:06:21 PM
USRM News: Significant Updates on the Following Companies and New Coverage 04/20/2017 09:00:00 AM
USRM News: Grey Cloak Tech, Inc. (OTC Pink: GRCK), Acquires $6.4mm ShareRails, Inc. – $1.7 million in Sales, 300% Growth 04/12/2017 08:49:04 AM
USRM News: Grey Cloak Tech, Inc. (OTC Pink: GRCK), Acquires $6.4mm ShareRails, Inc. – $1.7 million in Sales, 300% Growth 04/12/2017 08:47:59 AM
USRM News: Statement of Changes in Beneficial Ownership (4) 03/31/2017 04:02:24 PM
#59623  Sticky Note TOP TEN REASONS I'M LONG ON $USRM RIGHT NOW. TheHungryHippo 05/13/17 01:34:26 AM
#52397  Sticky Note This is the guy who is investing up Vita Nova Stocks 04/15/17 09:22:22 AM
#42457  Sticky Note THIS IS A MUST READ slam4202 03/30/17 07:05:37 AM
#26891  Sticky Note $USRM ALL IN ONE DD Post for Investors: TheHungryHippo 03/09/17 05:25:50 AM
#26168  Sticky Note Thoughts? BluSkies 03/07/17 09:49:57 PM
#63236   RMAT will bring out the whales and much GoldenMind 05/23/17 08:07:10 PM
#63235   I'm with you man !! sorc92 05/23/17 08:04:43 PM
#63234   Might freaking explode into dollar land. TheHungryHippo 05/23/17 07:59:29 PM
#63233   If USRM is not approved no problem , Newlife2017 05/23/17 07:58:40 PM
#63232   Might dip little more BoilerRoom 05/23/17 07:56:55 PM
#63231   Indeed! RMAT Approval CONFIRMS all the DD! ;) Kramden1 05/23/17 07:55:02 PM
#63230   I agree with your Kramden1 05/23/17 07:51:17 PM
#63229   I'm holding after rmat as well.that is just Chicagojosh 05/23/17 07:47:51 PM
#63228   Meant to put a smiley face. :) atpavlovich 05/23/17 07:45:14 PM
#63227   :) atpavlovich 05/23/17 07:44:39 PM
#63225   ?? atpavlovich 05/23/17 07:43:05 PM
#63223   USRM Definitely getting some on next dip.... BoilerRoom 05/23/17 07:35:59 PM
#63222   If it gets approved , am not planning Newlife2017 05/23/17 07:35:09 PM
#63221   That would b awesome but more likely you easymoney 05/23/17 07:32:56 PM
#63220   Context dependent for sure. Will be approved tho. afterhoursearnings 05/23/17 07:30:32 PM
#63219   Went down 5% ... doom CRAZY $$$$$$$ 05/23/17 07:30:29 PM
#63218   lol no man...there is a ticker on this afterhoursearnings 05/23/17 07:28:53 PM
#63217   I believe it will be approved but if Newlife2017 05/23/17 07:28:11 PM
#63216   35%...they are still gonna open 10 clinics..and if afterhoursearnings 05/23/17 07:27:23 PM
#63215   And after June you'll say July and after Cdizz123 05/23/17 07:26:43 PM
#63214   Pre market Friday would be best imo. Whole afterhoursearnings 05/23/17 07:24:59 PM
#63213   I believe we will get news by June atpavlovich 05/23/17 07:23:57 PM
#63212   Not yet. Soon, though. -Jameson- 05/23/17 07:23:30 PM
#63211   Any news ? Newlife2017 05/23/17 07:21:34 PM
#63210   RMAT dough11 05/23/17 07:18:19 PM
#63209   IMO dough11 05/23/17 07:17:48 PM
#63208   This is gonna get some social media shares!! afterhoursearnings 05/23/17 07:10:44 PM
#63207   good luck here, should go soon. the other BULLET 05/23/17 07:07:02 PM
#63206   ATTENTION SELLERS : MUST READ tamtam84 05/23/17 07:03:47 PM
#63204   Damn skippy The writing is on the wall, Hippo -Jameson- 05/23/17 06:50:54 PM
#63203   We got this Work Harder 05/23/17 06:48:19 PM
#63202   Wake up people .! There is no way Joeymc77 05/23/17 06:45:47 PM
#63200   How much do you think guys this stock Newlife2017 05/23/17 06:43:51 PM
#63198   I see .... bring on the rmat . sorc92 05/23/17 06:39:51 PM
#63195   Abso-Fu@&in-Lutely! ;) Kramden1 05/23/17 06:35:41 PM
#63191   Well, there is one thing we know Kramden Work Harder 05/23/17 06:24:19 PM
#63190   USRM Friday isn't the day people have been BoilerRoom 05/23/17 06:18:46 PM
#63189   Some get it and some don't! ;) Kramden1 05/23/17 06:15:23 PM
#63188   IB is the nest best in the marker 0mn1 05/23/17 06:07:11 PM
#63187   Nice, man I'd love to get into that Work Harder 05/23/17 06:04:46 PM
#63186   Friday night? L. L. Kinahan's 10 year =•] I've got -Jameson- 05/23/17 05:56:54 PM
#63185   Gewd, I was getting concerned about you Work Harder 05/23/17 05:54:39 PM
#63184   Tullamore D.E.W. today. was on sale ;) -Jameson- 05/23/17 05:51:20 PM
#63183   Especially knowing Work Harder 05/23/17 05:48:49 PM
#63182   They can us Interactive Brokers & such Work Harder 05/23/17 05:46:08 PM
#63181   Shorts usually come around on Wednesday, then cover by -Jameson- 05/23/17 05:45:19 PM
#63180   ETRADE BoilerRoom 05/23/17 05:39:52 PM
#63179   RMATCOMING FRIDAY SETTING UP TO GET NEWS SPREAD moznoz 05/23/17 05:38:12 PM
#63178   People here keep talking about shorting , I'd sorc92 05/23/17 05:36:54 PM
#63177   I'm thinking about it Zues Work Harder 05/23/17 05:34:20 PM